Zhou Keshu相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)

针对接受一线全身治疗后外周T细胞淋巴瘤患者的 JAK1 选择性抑制剂 golidocitinib 的 II 期多中心维持治疗研究 (JACKPOT26)

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-026-01452-8

Wei, Juying; Cai, Qingqing; Zhang, Liling; Zou, Liqun; Li, Zengjun; Zhou, Keshu; Wu, Huijing; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Li, Wenyu; Lin, Li'e; Xiao, Qing; Wang, Erhua; Jing, Hongmei; Zheng, Meifang; Zhang, Hongyu; Gao, Yuhuan; Gao, Da; Chen, Lijia; Jin, Jie

细胞生物学

免疫/内分泌

发表日期：2026

文献求助收藏

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

对中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 患者使用吡托布替尼的综合分析：来自 3 期研究 BRUIN CLL-321 的结果

期刊:British Journal of Haematology

影响因子:3.8

doi:10.1111/bjh.70334

Yi, Shuhua; Cao, Jiang; Feng, Ru; Zhou, Keshu; Qiu, Lihua; Li, Fei; Yang, Hai Yan; Zhou, Hui; Hui, Wuhan; Cui, Jie; Huang, He; Zhu, Jiankun; Ye, Xiuhui; Sharman, Jeff; Qiu, Lugui

细胞生物学

发表日期：2026

文献求助收藏

Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting

多发性骨髓瘤的新兴治疗药物：2024 年 ASH 年会亮点

期刊:Biomarker Research

影响因子:11.5

doi:10.1186/s40364-025-00803-0

Zhang, Qing; Song, Yongping; Zhou, Keshu; Lin, Quande

多发性骨髓瘤

发表日期：2025

文献求助收藏

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study

tazemetostat（一种 EZH2 抑制剂）治疗中国复发/难治性滤泡性淋巴瘤患者的疗效和安全性：一项多中心、单臂 II 期研究

期刊:EClinicalMedicine

影响因子:10

doi:10.1016/j.eclinm.2025.103399

Cao, Junning; Chen, Guangliang; Qiu, Lihua; Zhang, Liling; Jiang, Ming; Cheng, Ying; Zhang, Qiaohua; Liu, Lihong; Li, Ping; Shuang, Yuerong; Wang, Huaqing; Xue, Hongwei; Wu, Huijing; Zheng, Meifang; Zhou, Keshu; Li, Zhiming; Jing, Hongmei; Yang, Wei; Zhu, Zunmin; Li, Wenyu; Wangwu, Jiaxuan; Huang, Heyu; Jia, Qiantao; Chen, Dongmei; Fan, Songhua; Shi, M Ming; Su, Weiguo

发表日期：2025

文献求助收藏

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study

格洛菲单抗与真实世界治疗方案在中国复发/难治性弥漫性大B细胞淋巴瘤三线及以上患者中的疗效比较：一项外部对照研究

期刊:Cancer Biology & Medicine

影响因子:8.4

doi:10.20892/j.issn.2095-3941.2025.0104

Zhou, Keshu; Wu, Huijing; Zhao, Xia; Tan, Xiaohong; Yan, Xiaojing; Liu, Haisheng; Su, Liping; Lan, Yukun; Xu, Jaihui; Zhou, Xiaohui; Shuang, Yuerong; Zhang, Huilai

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial

隆卡妥昔单抗治疗中国复发或难治性弥漫性大B细胞淋巴瘤患者：一项多中心、开放标签、单臂II期临床试验

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2024.284973

Lin, Ningjing; Sun, Xiuhua; Zhou, Hui; Zou, Liqun; Zhou, Keshu; Liu, Lihong; Yang, Haiyan; Hu, Kai; Cai, Qingqing; Liu, Yao; Jin, Jie; Zhang, Liling; Li, Wenyu; Guo, Ye; Yang, Wei; Luo, Feng; Wang, Zhenguang; Zhu, Rong; Yang, Lei; Song, Dan; Song, Yuqin; Zhu, Jun

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis

泽布替尼与奥瑞替尼治疗复发/难治性套细胞淋巴瘤患者疗效的间接比较：一项扩展随访分析

期刊:Advances in Therapy

doi:10.1007/s12325-025-03202-x

Deng, Lijuan; Song, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lv, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun

细胞生物学

发表日期：2025

文献求助收藏

Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial

阿卡替尼治疗中国复发/难治性慢性淋巴细胞白血病患者：一项开放标签、多中心 1/2 期试验的主要分析

期刊:Annals of Hematology

影响因子:2.4

doi:10.1007/s00277-024-05978-4

Yang, Shenmiao; Huang, Haiwen; Zhou, Keshu; Zhao, Xielan; Han, Yanqiu; Li, Lindong; Wang, Yujie; Liu, Xiaofeng; Li, Jianyong

细胞生物学

发表日期：2025

文献求助收藏

Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

amulirafusp alfa (IMM0306) 是一种由 CD20 单克隆抗体与 SIRPα 的 CD47 结合域融合而成的蛋白，用于评估其在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的安全性和有效性：一项 1/2 期研究

期刊:Journal of Hematology & Oncology

影响因子:40.4

doi:10.1186/s13045-024-01646-2

Yang, Jianliang; Song, Yongping; Zhou, Keshu; Li, Zhiming; Zhang, Mingzhi; Jing, Hongmei; Wang, Zhen; Yu, Li; Meng, Wei; Lu, Qiying; Tian, Wenzhi; Shi, Yuankai

单克隆抗体

多发性骨髓瘤

细胞生物学

发表日期：2024

文献求助收藏

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

在复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中，泽布替尼与伊布替尼的持续获益：ALPINE 研究的最终比较分析

影响因子:23.1

doi:10.1182/blood.2024024667

Brown, Jennifer R; Eichhorst, Barbara; Lamanna, Nicole; O'Brien, Susan M; Tam, Constantine S; Qiu, Lugui; Jurczak, Wojciech; Zhou, Keshu; Šimkovič, Martin; Mayer, Jiří; Gillespie-Twardy, Amanda; Ferrajoli, Alessandra; Ganly, Peter S; Weinkove, Robert; Grosicki, Sebastian; Mital, Andrzej; Robak, Tadeusz; Osterborg, Anders; Yimer, Habte A; Wang, Megan; Salmi, Tommi; Wang, Liping; Li, Jessica; Wu, Kenneth; Cohen, Aileen; Shadman, Mazyar

细胞生物学

发表日期：2024

文献求助收藏